Mesulergine

Mesulergine is a psychoactive drug of the ergoline family that has been studied for its potential use in the treatment of Parkinson's disease and dementia. It is classified as a serotonin antagonist and reuptake inhibitor (SARI) and has been found to act as an antagonist at the 5-HT2A receptor, 5-HT2B receptor, and 5-HT2C receptor.

Pharmacology[edit | edit source]

Mesulergine acts as a serotonin antagonist and reuptake inhibitor, meaning it blocks the action of serotonin at certain receptors in the brain and also prevents the reuptake of serotonin, thereby increasing the amount of this neurotransmitter available in the brain.

The drug has been found to act as an antagonist at the 5-HT2A receptor, 5-HT2B receptor, and 5-HT2C receptor. These receptors are all types of serotonin receptors, and their blockade by mesulergine is thought to be responsible for its potential therapeutic effects.

Clinical Use[edit | edit source]

Mesulergine has been studied for its potential use in the treatment of Parkinson's disease and dementia. However, as of now, it is not approved for any medical use in most countries.

In clinical trials, mesulergine has been found to improve symptoms of Parkinson's disease, including tremors, rigidity, and bradykinesia. It has also been found to improve cognitive function in patients with dementia.

Side Effects[edit | edit source]

Like all drugs, mesulergine can cause side effects. These can include nausea, vomiting, dry mouth, and dizziness. In rare cases, it can cause more serious side effects such as hallucinations, confusion, and severe dizziness.